Corona and the Pharma Industry

In 2023, the intellectual property landscape in Israel had to deal with challenges created by the ongoing conflict. Despite these obstacles, interesting developments emerged, particularly in artificial intelligence and security, shaping a compelling trajectory for the year. Overall, it was an exceptionally intriguing year.

On March 27, 2024, the Israeli District Court in Jerusalem rendered a significant ruling in a Novartis case concerning Patent Term Extensions (PTEs), which has broad implications for pharmaceutical patent owners. The court accepted an appeal against a decision of the Registrar of Patents to revoke a PTE, which establishes the principle that PTEs in Israel are linked to the active ingredient and not to the first pharmaceutical preparation used to file the PTE application.

Joshua M. Peck, in discussion with Lilach Luzzatto Shukrun, Head of Engineering and Medical Devices at The Luzzatto Group, reports on the growth in three technology areas that are revolutionizing innovation in Israel.